Rhophylac FDA Approval History
FDA Approved: Yes (First approved February 12, 2004)
Brand name: Rhophylac
Generic name: Rh0(D) immune globulin intravenous (human)
Dosage form: Injection
Company: ZLB Bioplasma AG, Switzerland
Treatment for: Rh-Isoimmunization, Idiopathic Thrombocytopenic Purpura
Rhophylac (Rh0(D) immune globulin intravenous (human)) is indicated for the suppression of rhesus (Rh) isoimmunization in pregnancy, obstetric conditions and incompatible transfusions, and the treatment of immune thrombocytopenic purpura.
Development Timeline for Rhophylac
|Apr 2, 2007||FDA Approves Rhophylac for the Treatment of Immune ThrombocytopenicPurpura (ITP)|
|Feb 12, 2004||Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.